- Monopar Therapeutics Inc MNPR shared data from its ongoing open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma.
- The previous exploratory clinical trials of camsirubicin in cancer patients showed the potential to treat patients at high doses for a year or more.
- The preclinical and exploratory clinical studies showed no irreversible cardiac toxicity with camsirubicin, as observed with doxorubicin, one of the most commonly used anticancer drugs worldwide.
- 11 patients were enrolled in the phase 1b clinical trial. 5 out of 10 patients showed stable disease after 12 weeks. 1 patient met the criteria for SD at the first CT scan (6 weeks) but unfortunately died of COVID-19 and was unevaluable at the 12 week CT scan.
- The ASTS subtype patients who achieved stable disease on camsirubicin are consistent with those who are more likely to respond to doxorubicin.
- The study is currently in the fourth dose cohort (520 mg/m2), almost double the study’s starting dose.
- Drug-related clinical cardiotoxicity was not observed in any patient. The study is continuing and the dose escalated as there is no evidence that the maximum tolerated dose is being reached.
- Price promotion: MNPR shares are up 0.36% at last check Wednesday to $2.82.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
